Tumor-associated antigen (polyclonal) (TAA)

This therapeutic approach does not target a single molecule but instead utilizes a broad spectrum of tumor-associated antigens (TAAs) to stimulate the immune system (National Cancer Institute, 2024). By using engineered dendritic cells loaded with whole-tumor-RNA or tumor lysates, the therapy presents a diverse array of epitopes to the patient's T-cells (Liau et al., 2023). This process induces a polyclonal T-cell response, which is designed to address the inherent heterogeneity of malignant tumors (Van Willigen et al., 2018). Such a strategy is particularly relevant in cancers like glioblastoma, where targeting a single antigen often leads to immune evasion through antigen loss (PubMed: 30634452). The dendritic cells act as professional antigen-presenting cells, orchestrating a complex immune cascade that involves both CD4+ and CD8+ T-cell activation. Unlike traditional small molecules or monoclonal antibodies, the target here is the collective antigenic profile of the individual patient's tumor. This personalized immunotherapy aims to create a durable immune memory to prevent disease recurrence.

Other names

Whole-tumor-derived antigensTumor-associated antigensNeoantigensTumor lysate antigensTumor RNA-derived antigensPolyclonal tumor antigens

The therapy involves the ex vivo loading of autologous dendritic cells with a broad spectrum of tumor-derived antigens (via RNA or lysate), followed by re-administration to the patient to prime a polyclonal T-cell response against the tumor.